Showing results (571-580 of 636) with videos related to
Sort By:
Pageof 64
Journal of the American College of Cardiology|January 15, 2025
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFShingo Matsumoto, Pardeep S Jhund, Alasdair D Henderson, et al.JAMA Cardiology|November 17, 2024
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialMisato Chimura, Xiaowen Wang, Pardeep S Jhund, et al.European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.Journal of the American College of Cardiology|December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection FractionMikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.Circulation. Heart Failure|August 27, 2022
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER TrialAlexander Peikert, Felipe A Martinez, Muthiah Vaduganathan, et al.European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.Journal of the American College of Cardiology|November 20, 2024
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart FailureMikhail N Kosiborod, David Z I Cherney, Akshay S Desai, et al.European Journal of Heart Failure|June 26, 2024
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fractionMingming Yang, Toru Kondo, Pardeep S Jhund, et al.Pageof 64